MedTrace Logo

Phase 1 Study to Assess AER-271

NCT03804476 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-07-09

No results posted yet for this study

Summary

The objective of this Phase 1 trial is to assess the safety, tolerability and pharmacokinetics of AER-271 in health subjects.

Conditions

  • Stroke
  • Stroke, Acute
  • Stroke, Ischemic

Interventions

DRUG

AER-271

AER-271, the test article for this study.

DRUG

Placebo

Placebo control for this study.

Sponsors & Collaborators

  • Covance

    collaborator INDUSTRY

  • Aeromics, Inc.

    lead INDUSTRY

Principal Investigators

  • Paul R McGuirk, PhD · Aeromics, Inc.

  • Alex King, MD · Covance

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-26
Primary Completion
2019-07-18
Completion
2019-08-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03804476 on ClinicalTrials.gov